Bellicum Pharmaceuticals (BLCM) 10-Q2019 Q1 Quarterly report

Filed: 7 May 19, 4:32pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: adolescent, Assent, Atara, Biotec, Brexit, California, CCPA, Celyad, climate, cyber, cyclophosphamide, denominated, description, destruction, detrimental, discharge, divergent, doubt, downturn, dubbed, earliest, EBMT, economy, epidermal, evolving, exit, expedient, fallback, Fate, FCA, feedback, floating, fluid, free, function, furlough, Gamida, geopolitical, German, hand, hindsight, illiquidity, immunomodulatory, Immunopharma, implicit, incremental, indefinitely, index, inhibitory, intangible, Iovance, language, LIBOR, likewise, London, Lyell, Magenta, Medica, Medigene, microenvironment, Miltenyi, minimum, modification, modulate, modulating, modulation, movement, Mustang, notably, notification, Overnight, overriding, Parliament, people, pivotal, Poseida, postpone, prolonged, recoverability, referendum, registry, rejected, reminding, rolling, ROU, Royal, screening, shut, SOFR, SRC, statutory, steering, sterling, strain, stringent, suppressive, tenant, THRIVE, tubing, unclear, unreleased, Unum, unused, urge, user, veterinary, weak, word, worldwide, Zone

Removed: accelerating, accrue, adjust, affinity, appointment, arisen, assessment, audit, backup, bill, cancellation, capability, consultancy, Conversely, differentiation, discontinuation, enabling, faster, FDIC, fluctuate, forfeited, fourth, front, improved, inducement, intrinsic, Juno, Kite, listed, malignant, match, modular, mutual, newly, NIH, NOL, optimization, Pfizer, PRAME, precisely, preservation, professional, RAC, rating, recombinant, reconstitution, redirect, repaid, reprice, requested, reserved, September, SIPC, sooner, speculation, sponsored, summary, Treasurer, underlying, Vice, wrong

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

BLCM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 (the “Report”) of Bellicum Pharmaceuticals, Inc. (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, the undersigned, in their capacities as officers of the Registrant, do each hereby certify, that, to the best of such officer’s knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.



	/s/ Richard A. Fair
	Richard A. Fair
	President and Chief Executive Officer
	(Principal Executive Officer)
	May 7, 2019


	/s/ Atabak Mokari
	Atabak Mokari
	Chief Financial Officer
	(Principal Financial Officer)
	May 7, 2019

This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the report), irrespective of any general incorporation language contained in such filing.